Innovative Medical Technology

Neurotron, Incorporated

   Innovative Medical Technology

                 Established 1981

Neurometer® Clinical Applications Background, Neurophysiology & Neuropathology

 Patient Care


 Press Releases






 Clinical Apps








More than 30 years after leaving the laboratory for clinical applications ranging from Podiatry to Neurology and dozens of other specialties in-between, the Neurometer® evaluation is proven to provide unique functional diagnostic measures of sensory nerve conduction thresholds (sNCTs).  We use minimum amounts of painless electrical stimulus to consistently elicit a nerve response, the Current Perception Threshold (CPT).  Specific diagnostic applications for polyneuropathy, radiculopathy and other conditions are reviewed below.

The Neurometer diagnostic neurostimulator generates a constant current stimulus by monitoring and compensating for tissue impedance variations. The stimulus evokes responses that quantify the functional integrity of each of the three major sub-populations of sensory nerve fibers. Specifically, Aβ, Aδ & C fiber groups are selectively stimulated by sinusoid waveform currents of 2000 Hz, 250 Hz and 5 Hz respectively. Using small surface electrodes, this test generates discrete double-blinded CPT measures (p<0.006) representing minimum detectable current intensities (+/- 20 μAmp.) for each fiber type.


Advantages of the Neurometer Evaluation
Common metabolic/toxic and progressive neuropathies affect sensory nerves before motor nerves. Affected sensory nerves pass through reversible stages of hyperesthesia (often sub-clinical) then hypoesthesia and anesthesia. These sensory impairments occur in specific nerve fiber sub-populations. CPT studies have the unique capacity to evaluate the full spectrum of sensory nerve function in all the major fiber sub-populations. Patients are frequently asymptomatic in the earliest stages. The earliest stage of the pathologic process is usually the easiest phase to effectively intervene. The Neurometer detects hyperesthetic sensory neuropathy in non-diabetics with impaired glucose tolerance and in non-diabetic obese individuals. This ability to detect subclinical abnormalities in conditions known to carry a high risk of polyneuropathy is a tremendous clinical diagnostic advantage. It also detects the hypoesthesia of advanced neuropathic conditions as well as nerve regeneration.  A table is provided presenting a comparison of features between various neurodiagnostic testing procedures.

Research publications confirm that sensory impairments ranging from polyneuropathies (diabetic, demyelinating, toxic) to compressive lesions (Carpal Tunnel Syndrome), radiculopathies, spinal cord lesions as well as regeneration may be neuroselectively evaluated. Additional applications of the Neurometer include pharmaceutical, cosmetic, environmental and laboratory animals.


The Neurometer Evaluation

Automated double-blind testing methodology is used to determine the painless measures. It is based on the same psycho-physical principles used in routine hearing tests. The painless stimulus is characterized as “tingling”, “prickling”, or “buzzing”. Qualitative measures such as warm, cold, vibration, touch etc. are not a factor.

Electrodes are positioned at the prescribed test site and held in place with tape. Directions for the technician are displayed on the LCD screen. The subject is instructed to press a button until a stimulus is detected at the site of the electrode(s) and then release the button. At this point the painless CPT measure is verified using Compliance Guard
® software. This effectively monitors responses for consistency.  Depending on the test mode the standardized automated double-blind CPT measures from all 3 major sub-populations of nerve fibers requires 3-8 minutes per nerve/site.  CPT measures are then classified by comparison to the internationally validated normative database.



top of page      Previous page     Home



The entire contents of this web site are Copyright 1996-2010, Neurotron, Incorporated

Est. 1981, Baltimore, MD, USA.  All rights reserved, worldwide

rev 10/16/09